Drug Search Results
More Filters [+]

GEO-MVA

Alternative Names: GEO-MVA
Latest Update: None
Latest Update Note: None

Product Description

GeoVax obtained rights from the U.S. NIH to develop MVA as a vaccine for smallpox and Mpox (GEO-MVA), as well as also having rights from the NIH to use MVA as a vaccine vector. GeoVax also holds exclusive rights to use the City of Hope Medical Center's synthetic MVA (sMVA) platform for the manufacture and distribution of COVID-19 vaccines including GEO-CM04S1, our multi-antigenic COVID-19 vaccine currently in multiple Phase 2 studies. (Sourced from: https://www.geovax.com/technology/mva-technology-overview)

Mechanisms of Action: Vaccine

Novel Mechanism: No

Modality: Vaccine

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: GeoVax
Company Location: SMYRNA GA 30080
Company CEO: David A. Dodd
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for GEO-MVA

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 0: Monkeypox

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title